ArticleTranslational cancer research2013
Tumor microenvironment and nanotherapeutics.
Article in Translational cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Understanding DMG: current treatment options and prospective solutions using nanoparticles.Drug delivery and translational research · 2026Review
- Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti-Tumor Drug Delivery.Macromolecular rapid communications · 2026Review
- Multi-epitope ligand-conjugated nanoparticles for tumor neoantigen targeting: advancing molecular precision in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Harnessing the Power of Nanocarriers to Exploit the Tumor Microenvironment for Enhanced Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.Molecular cancer · 2024Review
- Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.Cancer medicine · 2024Review
- Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice.International journal of molecular sciences · 2024Article
- Theranostic and Combined Approaches Exploiting Multifunctional Gold Nanoclusters in Tumoral Ecosystems: A Paradigm Shift in Precision Oncology.Current radiopharmaceuticals · 2024Review
- Deep Insight of Design, Mechanism, and Cancer Theranostic Strategy of Nanozymes.Nano-micro letters · 2023Review
- Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy.Materials today. Bio · 2023Article
- Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons.The Journal of membrane biology · 2023Review
- Metallic Nanoparticles: Their Potential Role in Breast Cancer Immunotherapy via Trained Immunity Provocation.Biomedicines · 2023Review
- Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.RSC advances · 2023Review
- Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles.Journal of functional biomaterials · 2023Review
- Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer.Pharmaceutics · 2023Article
- The Recent Development of Multifunctional Gold Nanoclusters in Tumor Theranostic and Combination Therapy.Pharmaceutics · 2022Review
- Construction and evaluation of curcumin upconversion nanocarriers decorated with MnODrug delivery and translational research · 2022Article
- Review
- CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.Molecular therapy oncolytics · 2022Review
- Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent studies delineate a predominant role for the tumor microenvironment in tumor growth and progression. Improved knowledge of cancer biology and investigation of the complex functional interrelation between the cellular and noncellular compartments of the tumor microenvironment have provided an ideal platform for the evolution of novel cancer nanotherapies. In addition, multifunctional "smart" nanoparticles carrying imaging agents and delivering multiple drugs targeted preferentially to the tumor/tumor microenvironment will lead to early diagnosis and better treatment for patients with cancer. The emerging knowledge of the tumor microenvironment has enabled rational designing of nanoparticles for combinatorial treatment strategies that include radiotherapy, antiangiogenesis and chemotherapy. This multimodality approach is thus expected to achieve therapeutic efficacy and enhance the quality of life of cancer patients. This review highlights the unique characteristics of the tumor microenvironment that are exploited by nanotechnology to develop novel drug delivery systems aimed to target the tumor/tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.